Cyclosporine A and Mycophenolate Mofetil vs Cyclosporine A and Methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings

F. Neumann, T. Graef, C. Tapprich, M. Vaupel, U. Steidl, U. Germing, R. Fenk, A. Hinke, R. Haas, G. Kobbe

Research output: Contribution to journalArticle

69 Scopus citations

Abstract

The combination of Cyclosporin A (CSA) and Methotrexate (MTX) is considered to be the standard regimen for the prevention of graft-versus-host disease (GVHD) after stem cell transplantation (SCT) from HLA-identical siblings. Mycophenolate Mofetil (MMF) has been widely used for GVHD prophylaxis after nonmyeloablative SCT, but experience following myeloablative therapy is still limited. We retrospectively compared CSA/MTX and CSA/MMF in 93 patients (median age 35 years, range 17-59 years, male subjects 48, female subjects 45) with acute myeloid leukemia (n = 33), myelodysplastic syndrome (MDS) (n = 3), acute lymphoblastic leukemia (ALL) (n = 20) or chronic myeloid leukemia (n = 37) who received CSA/MMF (n = 26) or CSA/MTX (n = 67) as GVHD prophylaxis following high-dose therapy and allogeneic SCT from HLA-identical siblings. No statistically significant differences were found in overall survival, relapse rate, treatment-related mortality and acute or chronic GVHD. Time to myeloid recovery was significantly shorter in patients who received CSA/MMF. We conclude that the combination of CSA/MMF appears equivalent to CSA/MTX for GVHD prophylaxis in patients receiving conventional-intensity SCT from HLA-identical siblings.

Original languageEnglish (US)
Pages (from-to)1089-1093
Number of pages5
JournalBone Marrow Transplantation
Volume35
Issue number11
DOIs
StatePublished - Jun 1 2005
Externally publishedYes

Keywords

  • Cyclosporine
  • GVHD
  • Methotrexate
  • Mycophenolate Mofetil
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Cyclosporine A and Mycophenolate Mofetil vs Cyclosporine A and Methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings'. Together they form a unique fingerprint.

  • Cite this